TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC raised its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 52.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,989 shares of the company's stock after purchasing an additional 2,065 shares during the quarter. OneDigital Investment Advisors LLC's holdings in TransMedics Group were worth $403,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in TransMedics Group by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock valued at $226,700,000 after purchasing an additional 40,860 shares during the last quarter. FIL Ltd boosted its holdings in TransMedics Group by 28.0% in the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after purchasing an additional 218,961 shares during the last quarter. Braidwell LP acquired a new position in shares of TransMedics Group in the fourth quarter worth about $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of TransMedics Group by 16.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock worth $56,307,000 after acquiring an additional 128,474 shares during the period. Finally, Mackenzie Financial Corp raised its position in shares of TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock worth $51,635,000 after acquiring an additional 349,403 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of TransMedics Group stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider directly owned 13,955 shares in the company, valued at $1,950,909. This trade represents a 4.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David Weill sold 732 shares of TransMedics Group stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director owned 12,134 shares in the company, valued at $1,503,159.92. This represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 12,418 shares of company stock valued at $1,512,613. Insiders own 7.00% of the company's stock.

TransMedics Group Stock Up 3.9%

TMDX stock traded up $4.42 during midday trading on Monday, hitting $116.88. The company's stock had a trading volume of 1,284,133 shares, compared to its average volume of 1,378,619. The company has a quick ratio of 8.32, a current ratio of 9.10 and a debt-to-equity ratio of 1.92. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The firm has a market capitalization of $3.95 billion, a P/E ratio of 85.94 and a beta of 2.06. The firm has a 50-day simple moving average of $125.49 and a 200-day simple moving average of $90.85.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to analysts' expectations of $123.39 million. TransMedics Group had a net margin of 10.03% and a return on equity of 21.88%. The company's revenue for the quarter was up 48.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.35 EPS. As a group, equities analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TMDX. Piper Sandler reiterated an "overweight" rating and issued a $145.00 price objective (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Finally, Oppenheimer upped their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $127.33.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.